Last10K.com

Alexion Pharmaceuticals, Inc. (ALXN) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

SEC Filings

Alexion Pharmaceuticals, Inc.

CIK: 899866 Ticker: ALXN




a2016earningsreleaseimagea27.jpg
Alexion Reports Fourth Quarter and Full Year 2019 Results

4Q19 total revenues of $1,384.3 million, a 23 percent increase over 4Q18

4Q19 GAAP diluted EPS of $4.00; non-GAAP diluted EPS of $2.71

Received Japanese approval for SOLIRIS® (eculizumab) for neuromyelitis optica spectrum disorder (NMOSD)

Established ULTOMIRIS® (ravulizumab) as market leader for PNH in U.S., Germany and Japan within first year of launch

Continued strong SOLIRIS gMG and NMOSD launches, making neurology largest franchise in U.S.

Expanded pipeline with 19 clinical-stage development programs planned for 2020 across 10 assets, including 2 Factor D inhibitors, following completion of Achillion acquisition

BOSTON, January 30, 2020 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2019. Total revenues for the full year of 2019 were $4,991.1 million, a 21 percent increase compared to 2018. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $45.1 million, inclusive of hedging activities. On a GAAP basis, diluted EPS for the full year of 2019 was $10.70, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property, compared to $0.35 in the prior year, inclusive of $1,183.0 million of expense related to the value of the in-process research and development assets acquired in 2018. Non-GAAP diluted EPS for the full year of 2019 was $10.53, a 33 percent increase versus the prior year.

Total revenues in the fourth quarter were $1,384.3 million, a 23 percent increase compared to the same period in 2018. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $13.1 million, inclusive of hedging activities. On a GAAP basis, diluted EPS in the quarter was $4.00, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property, compared to $(0.20) in the prior year, inclusive of $379.3 million of expense related to the value of the in-process research and development asset acquired in connection with our acquisition of Syntimmune in the fourth quarter of 2018. Non-GAAP diluted EPS for the fourth quarter of 2019 was $2.71, a 27 percent increase versus the fourth quarter of 2018.

"In 2019, we continued to strengthen the foundation of our business by executing on our strategy to lead, expand and diversify. Our key achievements include establishing ULTOMIRIS as the market leader in PNH within the first year of launch, expanding our C5 portfolio to make neurology our largest franchise in the U.S., and further diversifying our pipeline with seven business development deals adding five clinical-stage assets to our portfolio," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. "I am confident we are well positioned for the future and will build on our momentum in 2020, with a continued focus on delivering long-term shareholder value by advancing our mission of developing and delivering transformative medicines for people with rare diseases."
 

1

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, January 30, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alexion Pharmaceuticals, Inc..

Continue

Assess how Alexion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information Document
Consolidated Balance Sheets (Parenthetical)
Consolidated Balance Sheets Consolidated Balance Sheets
Consolidated Statement Of Comprehensive Income
Consolidated Statement Of Comprehensive Income (Parentheticals)
Consolidated Statements Of Operations
Statement Of Cash Flows
Statement Of Shareholders' Equity
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (Schedule Of Accrued Expenses) (Details)
Accrued Expenses (Tables)
Acquisitions
Acquisitions (Asset Acquisition) (Details)
Acquisitions (Narrative) (Details)
Acquisitions (Summary Of Total Consideration) (Details)
Acquisitions (Syntimmune) (Details)
Acquisitions (Tables)
Acquisitions (Wilson Acquisition) (Details)
Business Overview And Summary Of Significant Accounting Policies
Business Overview And Summary Of Significant Accounting Policies (Earnings Per Common Share) (Details)
Business Overview And Summary Of Significant Accounting Policies (Inventories) (Details)
Business Overview And Summary Of Significant Accounting Policies (Narrative) (Details)
Business Overview And Summary Of Significant Accounting Policies (Policies)
Business Overview And Summary Of Significant Accounting Policies (Receivables And Contract Liabilities) (Details)
Business Overview And Summary Of Significant Accounting Policies (Tables)
Commitments And Contingencies
Commitments And Contingencies (Narrative) (Details)
Debt
Debt (Details)
Debt - Schedule Of Maturities Of Long-Term Debt (Details)
Debt Debt (Tables)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Narrative) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Interest Rate Derivatives) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Offsetting Assets And Liabilities) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details)
Derivative Instruments And Hedging Activities (Tables)
Derivative Instruments And Hedging Activities Schedule Of Cash Flow Hedges In Aoci (Details)
Employee Benefit Plans
Employee Benefit Plans (Narrative) (Details)
Employee Benefit Plans (Schedule Of Change In Benefit Obligation) (Details)
Employee Benefit Plans (Schedule Of Change In Plan Assets) (Details)
Employee Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost) (Details)
Employee Benefit Plans (Schedule Of Estimated Future Benefit Payments) (Details)
Employee Benefit Plans (Schedule Of Other Changes In Plan Assets And Benefit Obligations Recognized In Other Comprehensive Income) (Details)
Employee Benefit Plans (Schedule Of Weighted Average Assumptions Used To Calculate Net Periodic Benefit Cost And The Actuarial Present Value Of Projected Benefit Obligations) (Details)
Employee Benefit Plans (Tables)
Fair Value Measurement
Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)
Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details)
Fair Value Measurement (Tables)
Income Taxes
Income Taxes (Narrative) (Details)
Income Taxes (Reconciliation Of The Statutory U.S. Federal Income Tax Rate To Effective Income Tax Rate) (Details)
Income Taxes (Reconciliation Of Unrecognized Tax Benefits) (Details)
Income Taxes (Schedule Of Components Of Deferred Tax Assets And Liabilities) (Details)
Income Taxes (Schedule Of Components Of Income Tax Provision (Benefit)) (Details)
Income Taxes (Schedule Of Income Tax Provision (Benefit) On Income Before Income Taxes) (Details)
Income Taxes (Tables)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (Narrative) (Details)
Intangible Assets And Goodwill (Schedule Of Changes In The Carrying Amount Of Goodwill) (Details)
Intangible Assets And Goodwill (Schedule Of Intangible Assets And Goodwill) (Details)
Intangible Assets And Goodwill (Tables)
Leases
Leases (Tables)
Leases - Aggregate Future Minimum Non-Cancellable Commitments Under Leases (Details)
Leases - Cash Flow Information (Details)
Leases - Lease Additional Information (Details)
Leases - Lease Assets And Liabilities (Details)
Leases - Lease Cost (Details)
Leases - Lease Maturity (Details)
Leases - Narrative (Details)
Marketable Securities
Marketable Securities (Available-For-Sale Debt Securities By Contractual Maturity) (Details)
Marketable Securities (Available-For-Sale Securities By Classification In Balance Sheet) (Details)
Marketable Securities (Narrative) (Details)
Marketable Securities (Summary Of Avaiable-For-Sale Securities Held) (Details)
Marketable Securities (Tables)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Notes)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Reclassifications Out Of Accumulated Other Comprehensive Income) (Details)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Schedule Of Accumulated Other Comprehensive Income (Loss)) (Details)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Tables)
Other Investments
Other Investments (Details)
Property, Plant And Equipment, Net
Property, Plant And Equipment, Net (Details)
Property, Plant And Equipment, Net (Tables)
Quarterly Financial Information (Unaudited)
Quarterly Financial Information (Unaudited) (Details)
Quarterly Financial Information (Unaudited) (Tables)
Restructuring And Related Expenses
Restructuring And Related Expenses (Details)
Restructuring And Related Expenses (Tables)
Restructuring And Related Expenses - Reconciliation Of Restructuring Reserve (Details)
Segment Information
Segment Information (Tables)
Segment Information - Net Product Sales (Details)
Share-Based Compensation
Share-Based Compensation (Narrative) (Details)
Share-Based Compensation (Schedule Of Components Of Allocated Share-Based Compensation Expense And Capitalization Of Share Based Compensation Expense) (Details)
Share-Based Compensation (Schedule Of Ranges Of Weighted Average Assumptions) (Details)
Share-Based Compensation (Schedule Of Status Of Non-Vested Restricted Stock) (Details)
Share-Based Compensation (Schedule Of Status Of Stock Option Plans) (Details)
Share-Based Compensation (Tables)
Stockholders' Equity
Stockholders' Equity (Details)
Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0000899866-20-000012
Submitted to the SEC: Tue Feb 04 2020 6:30:53 AM EST
Accepted by the SEC: Tue Feb 04 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/alxn/0000899866-20-000012.htm